- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors
April 4th 2017, 10:20pm
A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.
Novel RAF Inhibitor Active Across Multiple Tumor Types
April 4th 2017, 8:16pm
Treatment with the RAF dimer inhibitor BGB-283 led to clinical benefit for patients with BRAF V600-mutated melanoma, papillary thyroid cancer, and ovarian cancer.
CAR T-Cell Response Rate Tops 80% in NHL Trial
April 4th 2017, 7:40pm
Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.
Dr. Brahmer on 5-Year Follow-Up Data for Nivolumab in NSCLC
April 4th 2017, 2:22am
Julie R. Brahmer, MD, associate professor of Oncology, Bloomberg Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, discusses 5-year follow-up data from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC).
Jacob Gersh Discusses the CyberKnife
April 3rd 2017, 11:46pm
ACCC Annual Meeting, CANCERSCAPE
Jacob Gersh, PhD, lead physicist at the Gibbs Cancer Center & Research Institute, discusses the CyberKnife.
Dr. Patel Discusses the Cancer Drug Coverage Parity Act
April 3rd 2017, 11:35pm
ACCC Annual Meeting, CANCERSCAPE
Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.
Dr. Luke Discusses the Controversy Surrounding Ipilimumab/Nivolumab Combo in Melanoma
April 3rd 2017, 9:49pm
Jason J. Luke, MD, assistant professor of Medicine, The University of Chicago Medicine, discusses the controversy surrounding the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in treatment-naïve patients with advanced melanoma, which was explored in the CheckMate-067 trial, during the AACR Annual Meeting.
Five-Year Survival Rate an Impressive 16% With Nivolumab in Advanced NSCLC
April 3rd 2017, 9:47pm
Long-term survival in patients with metastatic non–small cell lung cancer who received the immune checkpoint inhibitor nivolumab (Opdivo) has proven to be much higher than expected, with 16% of these patients surviving after 5 years, equivalent to about 4 times what would be expected with chemotherapy.
Nivolumab/Ipilimumab Combo Shows Modest OS Benefit in Advanced Melanoma in Updated Phase III Findings
April 3rd 2017, 9:24pm
The PD-1 and CTLA-4 inhibitor combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was associated with a 12% reduction in the risk of death versus nivolumab monotherapy in patients with treatment-naïve advanced melanoma.
Avelumab Further Demonstrates Durable Responses in Merkel Cell Carcinoma
April 3rd 2017, 9:03pm
Treatment with the PD-L1 inhibitor avelumab induced an objective response rate of 33% in patients with advanced Merkel cell carcinoma in the phase II JAVELIN Merkel 200 study, including 2 additional complete responses since the primary analysis.
Atezolizumab Yields Long-Term OS in mTNBC Subset
April 3rd 2017, 8:45pm
According to results presented at the 2017 AACR Annual Meeting, 10% of patients showed impressive long-term survival in a phase I study of single agent anti-PD-L1 atezolizumab (Tecentriq) in patients with metastatic triple-negative breast cancer.
Tumor Treating Fields Substantially Improve Survival in GBM
April 3rd 2017, 12:30am
Tumor treating fields reduced the risk of death by 37% and overall survival was extended by a median of 5 months for patients with glioblastoma multiforme, in a landmark analysis of the EF-14 trial.
Dual HER2 Targeting Effective in Refractory mCRC Subset
April 2nd 2017, 11:47pm
A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.
Neratinib Shows Promise in HER2-Mutated Cancers
April 2nd 2017, 9:06pm
The irreversible pan-HER tyrosine kinase inhibitor neratinib showed single-agent activity across cohorts of patients with HER2-mutant advanced cancers.
Dr. Stupp on Final Results for TTFields Added to Chemo in Glioblastoma
April 2nd 2017, 8:51pm
Roger Stupp, MD, professor, Neurological Surgery, and associate director, Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses final results of a randomized, multi-center, phase III trial investigating tumor treating fields (TTFields) added to standard chemotherapy in newly diagnosed glioblastoma during the AACR Annual Meeting.
Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL
April 2nd 2017, 8:10pm
Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.
ACCC Speaker Says Drug Pricing Reform May Gather Momentum
April 1st 2017, 1:37am
ACCC Annual Meeting, CANCERSCAPE
Jessica Turgon, MBA, of ECG Management Consultants says that changes in 340B Drug Pricing Program rules and the CMS physician payment formula are possible.
Clarifying the Role of Oncology Nurse Navigators
April 1st 2017, 1:36am
ACCC Annual Meeting, CANCERSCAPE
Tricia Strusowski, MS, RN, discusses the role of the oncology nurse navigator and how these staffers can help meet outcome and quality standards set by the CMS's OCM.
Dr. Crews Reflects on the Achievements of the ACCC During Her Presidency
March 31st 2017, 7:31pm
ACCC Annual Meeting, CANCERSCAPE
The outgoing president of the Association of Community Cancer Centers, Jennie Crews, MD, MMM, FACP reflects on her time as president and the achievements the ACCC made.
Federal Healthcare Policy Is Front and Center at CANCERSCAPE Conference
March 31st 2017, 3:46am
ACCC Annual Meeting, CANCERSCAPE
While at the annual CANCERSCAPE meeting of ACCC, Kavita Patel, MD, MS, comments on uncertainy in the healthcare environment and key policy to be aware of.